Document:

Lock-Up Agreement

 

___________ __, 2012

ICM Capital Markets Ltd.

888 Seventh Avenue, 17th Floor

New York, NY 10019

 

Ladies and Gentlemen:

 

The undersigned understands
that ICM Capital Markets Ltd. (the “Representative”) proposes to enter
into an Underwriting Agreement (the “Underwriting Agreement”) with Sunity Online Entertainment Limited,
a Cayman Islands exempted limited liability company (the “Company”), providing for the public offering (the
“Public Offering”) by the Underwriters named in the Underwriting Agreement of up to [●]
American Depositary Shares (“ADSs”) representing [●] ordinary shares
(“Securities”), par value $0.00249 per share, of the Company.

 

To induce the Representative to continue its
efforts in connection with the Public Offering, the undersigned hereby agrees that, without the prior written consent of the Representative,
it will not, during the period commencing on the date hereof and ending six months after the date of the final prospectus (the
“Prospectus”) relating to the Public Offering (the “Lock-Up Period”), (1) offer, pledge,
sell, contract to sell, grant, lend, or otherwise transfer or dispose of, directly or indirectly, any ADSs or capital stock of
the Company including ordinary shares (“Ordinary Shares”) or any securities convertible into or exercisable
or exchangeable for such ADSs or capital stock, or (2) enter into any swap or other arrangement that transfers to another, in whole
or in part, any of the economic consequences of ownership of such ADSs or capital stock, whether any such transaction described
in clause (1) or (2) above is to be settled by delivery of Company capital stock or such other securities, in cash or otherwise.
Notwithstanding the foregoing, the undersigned may transfer Ordinary Shares held by the undersigned without the prior consent of
the Representative in connection with (a) transactions relating to Ordinary Shares or other securities acquired in open market
transactions after the completion of the Public Offering, provided that no filing under Section 16(a) of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), shall be required or shall be voluntarily made in connection
with subsequent sales of Ordinary Shares or other securities acquired in such open market transactions, (b) transfers of Shares
or any security convertible into Ordinary Shares as a bona fide gift, by will or intestacy or to a family member or trust for the
benefit of a family member; provided that in the case of any transfer or distribution pursuant to clause (b), (i) each
donee or distributee shall sign and deliver a lock-up letter substantially in the form of this letter agreement and (ii) no filing
under Section 16(a) of the Exchange Act, reporting a reduction in beneficial ownership of Ordinary Shares (or ADSs representing
the same), shall be required or shall be voluntarily made during the Lock-up Period, (c) transfer of Ordinary Shares to a charity
or educational institution, or (d) if the undersigned, directly or indirectly, controls a corporation, partnership, limited liability
company or other business entity, any transfers of Ordinary Shares to any shareholder, partner or member of, or owner of similar
equity interests in, the undersigned, as the case may be, if, in any such case, such transfer is not for value. In addition, the
undersigned agrees that during the Lock-Up Period, without the prior written consent of the Representative, it will not make any
demand for or exercise any right with respect to the registration of any ADSs or Ordinary Shares or any security convertible into
or exercisable or exchangeable for such ADSs or Ordinary Shares. The undersigned also agrees and consents to the entry of stop
transfer instructions with the Company’s transfer agent(s) and/or registrar against the transfer of the undersigned’s
securities or Ordinary Shares except in compliance with this Agreement.

 

    	 

    	 

    
  

If (i) the Company issues an earnings release
or material news, during the last 17 days of the Lock-Up Period, or (ii) prior to the expiration of the Lock-Up Period, the Company
announces that it will release earnings results during the 16-day period beginning on the last day of the Lock-Up Period, the restrictions
imposed by this agreement shall continue to apply until the expiration of the 18-day period beginning on the issuance of the earnings
release, unless the Representative waives such extension.

 

No provision in this agreement shall be deemed
to restrict or prohibit the exercise or exchange by the undersigned of any option or warrant to acquire Ordinary Shares, or securities
exchangeable or exercisable for or convertible into Ordinary Shares, provided that the undersigned does not transfer the
Ordinary Shares acquired on such exercise or exchange during the Lock-Up Period, unless otherwise permitted pursuant to the terms
of this letter agreement. In addition, no provision herein shall be deemed to restrict or prohibit the entry into or modification
of a so-called “10b5-1” plan at any time (other than the entry into or modification of such a plan in such a manner
as to cause the sale of any Ordinary Shares or any securities convertible into or exercisable or exchangeable for Ordinary Shares
within the Lock-Up Period).

 

The undersigned understands that the Company
and the Representative are relying upon this letter agreement in proceeding toward consummation of the Public Offering. The undersigned
further understands that this agreement is irrevocable and shall be binding upon the undersigned’s heirs, legal representatives,
successors and assigns.

 

The undersigned understands that, if the Underwriting
Agreement is not executed by the Company, or if the Underwriting Agreement (other than the provisions thereof which survive termination)
shall terminate or be terminated prior to payment for and delivery of the ADSs and Ordinary Shares to be sold thereunder this agreement
shall be void and of no further force or effect.

 

Whether or not the Public Offering actually
occurs depends on a number of factors, including market conditions. Any Public Offering will only be made pursuant to an Underwriting
Agreement, the terms of which are subject to negotiation between the Company and the Representative.

 

	 	  Very truly yours,
	 	 
	 	  (Name):
	 	 
	 	  (Address)SECOND WAIVER

 

WHEREAS, the undersigned holders constitute the beneficial
owners (“Holders”) of 100% of the issued and outstanding Series A Convertible Preferred Stock, $0.001 par value per share
(“Series A Stock”) of Optex Systems Holdings, Inc. (“Company”); and

 

WHEREAS, Alpha Capital Anstalt has agreed to buy from the
Company 5,000,000 restricted shares of its Common Stock at a purchase price of $0.01 per share contingent on the irrevocable waiver
by the Holders of any past and future dividends on the Series A Stock, without further increase in the stated value per share;
and

 

WHEREAS, the Holders have determined
that they will derive future benefit by acting in this manner and that such future benefit is adequate consideration for entering
into such waiver;

 

IT IS HEREBY AGREED THAT:

 

Effective immediately, the Holders hereby waive all rights
they have under Section 5 of the Certificate of Designation of the Series A Stock both with respect to dividends which have accrued
up to the date of this Waiver and which may occur on or after the date of the Waiver, in perpetuity.

 

IN WITNESS WHEREOF, the undersigned have executed this Waiver
as of this 21st day of February, 2012.

 

ALPHA CAPITAL ANSTALT

 

	By: 	/s/ Konrad Ackermann	 
	 	Name: Konrad Ackermann	 
	 	Title: Director	 

 

SILEAS CORPORATION

 

	By: 	/s/ Stanley A. Hirschman	 
	 	Name: Stanley A. Hirschman	 
	 	Title: President	 

 

Consent/Acknowledgement:

 

The undersigned hereby acknowledges and consents to the terms
of this Second Waiver agreement as required by section 6.11 of the Security Agreement, dated as of February 20, 2009, between Sileas
Corp. ("Debtor") and Longview Fund, L.P. (the “Lender”).

 

LONGVIEW FUND, L.P.

 

	By: 	/s/ Peter Benz	 
	 	Name: Peter Benz	 
	 	Title: ChairmanAMENDMENT
TO AMENDED AND RESTATED MANUFACTURING AND

SUPPLY AGREEMENT

 

This Amendment to the Amended and Restated Manufacturing and Supply
Agreement (the “Amendment”) is entered into as of the 2nd day of February, 2012 and is deemed to
have come into effect on 1 January 2012 (the “Effective Date”), by and among Novartis Vaccines and Diagnostics, Inc.,
with its principal place of business located at 350 Massachusetts Avenue, Cambridge, MA 02139 USA (hereinafter “Novartis”),
and BioMimetic Therapeutics, Inc a Delaware corporation, with its principal place of business located at 389 Nichol Mill Lane,
Franklin, Tennessee 37067 (hereinafter “BMTI”).

 

BACKGROUND

 

WHEREAS, BMTI and Chiron Corporation (“Chiron”) previously
entered into an exclusive Manufacturing and Supply Agreement effective July 28, 2004 (“Original Agreement”)

 

WHEREAS, on 20 April 2006 Novartis acquired Chiron and thereby assumed
Chiron's rights and responsibilities under the Original Agreement. Under the Original Agreement Novartis had manufactured and supplied
BMTI with Product consisting of purified bulk recombinant human platelet growth factor as described in Novartis' FDA — approved
Biological License Application therefor, for use in the Exclusive Fields (as defined in the Agreement).

 

WHEREAS, the parties amended and restated the Original Agreement
and entered into the Amended and Restated Manufacturing and Supply Agreement effective December 1, 2009 to better define the parties'
rights and obligations regarding the Product, (the “Agreement”);

 

WHEREAS, the parties have agreed that Novartis will transfer the
manufacturing and testing activities for Products currently performed at Bayer's facility in Emeryville, California (a subcontractor
of Novartis) to the Facility (as defined in the Agreement) (the “Drug Substance Transfer”).

 

WHEREAS, subject to the terms and conditions set forth herein, the
parties hereto mutually desire to amend, modify and restate certain terms and conditions of the Agreement, as provided below.

 

NOW, THEREFORE, the parties hereto, intending to be legally bound,
agree as follows:

 

		1.	Definitions.

 

Unless otherwise defined herein, capitalized terms used in this
Amendment shall have the meanings set forth in the Agreement.

 

		2.	Amendments

 

The Parties agree that, as of the Effective Date, the Agreement
is amended as set forth in this Section 2.

 

		**	Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2
under the Securities Exchange Act of 1934, as amended, and has been filed separately with the Securities and Exchange Commission.

 

    	 

    	 	

    

 

		2.1.	A new section 2.3.3 of the Agreement shall be inserted as follows:

 

“Each party shall bear its own costs associated
with qualifying and licensing the Drug Substance Transfer changes covered by Novartis Change Control Numbers 25413, 32986, 306321,
312336, and 287336 for use in the Exclusive Field.”

 

		2.2.	Section 3.2 of the Agreement shall be deleted in its entirety and replaced with the following:

 

“3.2 Minimum Shelf Life. Subject to the specific
exceptions at paragraph 1 of Annex 2, at the time of delivery to BMTI’s designated carrier, the Product shall have a remaining
shelf life of not less than ** months.”

 

		2.3.	A new section 11.2(A) of the Agreement shall be inserted as follows:

 

“For the purposes of calculating Novartis’
minimum supply obligations pursuant to Section 11.2(a) of this Agreement, BMTI shall be deemed to have purchased ** grams of the
Product on 31 December 2011.”

 

		2.4.	Annex 2 of the Agreement shall be deleted in its entirety and replaced with the wording at Schedule 1 to this Amendment.

 

		3.	Integration.  The parties agree that except as otherwise expressly amended herein, all terms and conditions of the Agreement
as amended remain and shall remain in full force and effect. This Amendment shall hereafter be incorporated and be deemed part
of the Agreement and any future reference to the Agreement shall include the terms and conditions of this Amendment.

 

		4.	Applicable Law & Jurisdiction. This Amendment shall be governed by, and construed in accordance with the laws which
govern the Agreement, and the parties submit to the jurisdiction and dispute resolution provisions as set forth in the Agreement.

 

IN WITNESS WHEREOF, the parties hereto have caused this Amendment
to be executed by their duly authorized representatives, as of the date first written above.

 

	NOVARTIS VACCINES AND	 	BIOMIMETIC THERAPEUTICS, INC.
	DIAGNOSTICS INC.	 	 
	 	 	 
	/s/ Amol Chaubal	 	/s/ Earl Douglas
	By:  Amol Chaubal	 	By:  Earl Douglas
	        CFO US Operations	 	        General Counsel
	 	 	 
	Date:_____2/2/2012_________________	 	Date:_____2/21/12___________________

 

		**	Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2
under the Securities Exchange Act of 1934, as amended, and has been filed separately with the Securities and Exchange Commission.

 

    	 

    	 	

    

 

SCHEDULE 1

ANNEX 2

COMPENSATION

 

		1.	Product Prices

 

		A.	2011 Prices. Annual Product Prices will vary depending on the quantity ordered during the relevant year, as shown below.
Prices for 2011 were as follows and will be adjusted in accordance with this Annex 2 for each subsequent year during the term of
the Agreement:

 

	Quantity Ordered in 2011	 	Price/Gram
	**-** grams	 	$**
	**-** grams	 	$**
	Quantities above ** grams	 	$**

 

These prices shall be adjusted annually
in accordance with paragraph 8 below.

 

Notwithstanding Section 3.2 of the Agreement,
BMTI agrees to accept delivery of Product with a remaining shelf life of less than ** months, as follows:

 

	Year	 	Volume	 	Shelf Life
	2012	 	** gm	 	Shelf Life of Product to expire on **
	2013	 	** gm	 	Shelf Life of Product to expire on **

 

For the avoidance of doubt, the supply
of Products with a remaining shelf life of less than ** months shall count towards BMTI's Minimum Purchase Requirements set out
at paragraph 3 of this Annex 2.

 

		B.	Adjustment for Dosage Changes

 

If BMTI's dosage for Product in all of
its commercial product package configurations is less than or equal to ** mg/package, the sales price will be $** /gram.

 

		C.	Items included in the Product Price. Product Price will include:

 

		·	All raw materials

		·	The cost of operating the Facilities

		·	Performance of all in-process and release assays on each Product lot

		·	Disposal of waste streams

		·	Lot documentation Deliverables (QA disposition memorandum, COA and

COC for Product lot)

		·	Ongoing stability testing

 

		**	Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2
under the Securities Exchange Act of 1934, as amended, and has been filed separately with the Securities and Exchange Commission.

 

    	 

    	 	

    

 

		·	Resolution of manufacturing deviations

		·	Environmental monitoring

		·	Staff cGMP training, routine compliance audits and routine revalidation of

process and Facility equipment and systems, per SOPs

		·	Project coordination and progress reports

 

(Any analytical tests requested by BMTI
and performed by Novartis, other than Novartis' standard COA release testing shall be charged at the Additional Services Rate.)

 

		2.	Third Party Royalties

 

BMTI shall pay Novartis for third-party
royalties in accordance with its License Agreements, as provided in Section 5.3 of the Agreement, including the following:

 

	Licensing	 	Royalty	 
	Genentech Itakura/Riggs	 	 	1.0	%
	Genentech/WRF	 	 	1.0	%
	UC’s Kurjan	 	 	0.5	%

 

		3.	Minimum Purchase Requirements

 

		A.	BMTI shall purchase at least the following quantities of Product Purchase Requirements”) during the Term of this Agreement:

 

	Year	 	Minimum Purchase

(grams)
	2011	 	**
	2012	 	**
	2013	 	**
	2014 and thereafter	 	**

 

		4.	Travel

 

BMTI shall pay Novartis for any travel authorized
by BMTI, at cost plus 15%.

 

		5.	Additional Services

 

Subject to paragraph 8 below, BMTI shall
pay Novartis for any additional services approved in writing by BMTI at the rate of $**/person-hour, for services performed by
Novartis, and at cost plus **%, for services performed by independent contractors (jointly, the “Additional Services Rate”).

 

		6.	Payment Terms

 

Payments shall be due within ** days of BMTI's
receipt of the applicable invoice.

 

		**	Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2
under the Securities Exchange Act of 1934, as amended, and has been filed separately with the Securities and Exchange Commission.

 

    	 

    	 	

    

 

		7.	Early Termination Fee

 

If BMTI terminates the Agreement pursuant
to Section 10/2/3(a) thereof, BMTI shall pay Novartis a non-refundable, non-creditable termination fee equal to **, within ** days
of such termination.

 

		8.	Price Adjustment

 

Novartis may revise the prices of the
Products and the Additional Services Rate annually by any amount of increase in the United States Producer Price Index 2834 (Pharmaceutical
Preparations) during the preceding year.

 

		**	Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2
under the Securities Exchange Act of 1934, as amended, and has been filed separately with the Securities and Exchange Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00199-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00199-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00199-of-00352.parquet"}]]